title: Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy.
abstract: With >10,000,000 cancer survivors in the U.S. alone, the late effects of cancer treatment are a significant public health issue. Over the past 15 years, much work has been done that has led to an improvement in our understanding of the molecular mechanisms underlying the development of normal tissue injury after cancer therapy. In many cases, these injuries are characterized at the histologic level by loss of parenchymal cells, excessive fibrosis, and tissue atrophy. Among the many cytokines involved in this process, transforming growth factor (TGF)-beta1 is thought to play a pivotal role. TGF-beta1 has a multitude of functions, including both promoting the formation and inhibiting the breakdown of connective tissue. It also inhibits epithelial cell proliferation. TGF-beta1 is overexpressed at sites of injury after radiation and chemotherapy. Thus, TGF-beta1 represents a logical target for molecular therapies designed to prevent or reduce normal tissue injury after cancer therapy. Herein, the evidence supporting the critical role of TGF-beta1 in the development of normal tissue injury after cancer therapy is reviewed and the results of recent research aimed at preventing normal tissue injury by targeting the TGF-beta1 pathway are presented.
authors.affiliation: Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia, USA. manscher@mcvh-vcu.edu
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Anscher
mesh_terms: D000818:Animals; D015972:Gene Expression Regulation, Neoplastic / Q000528:radiation effects; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D055370:Lung Injury / Q000209:etiology / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011829:Radiation Dosage; D011832:Radiation Injuries / Q000517:prevention & control*; D018787:Radiation Oncology / Q000639:trends; D011878:Radiotherapy / Q000009:adverse effects; D018570:Risk Assessment; D015398:Signal Transduction; D053773:Transforming Growth Factor beta1 / Q000378:metabolism* / Q000502:physiology / Q000528:radiation effects; D057170:Translational Research, Biomedical
chemical_list: D053773:Transforming Growth Factor beta1